<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905853</url>
  </required_header>
  <id_info>
    <org_study_id>Sapp001</org_study_id>
    <nct_id>NCT00905853</nct_id>
  </id_info>
  <brief_title>Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy</brief_title>
  <acronym>VANISH</acronym>
  <official_title>Ventricular Tachycardia Ablation or Escalated aNtiarrhythmic Drugs in ISchemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Sapp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare aggressive antiarrhythmic therapy to catheter ablation for
      ventricular tachycardia in patients who have suffered prior myocardial infarction. The
      purpose of this study is to evaluate the optimal management of patients presenting with
      recurrent VT and receiving ICD therapy in spite of first-line antiarrhythmic drug therapy.
      The hypothesis is catheter ablation is superior to aggressive antiarrhythmic drug therapy for
      recurrent VT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, parallel group, two arm, unblinded, randomized clinical trial to
      compare two management strategies for patients with ischemic heart disease and recurrent ICD
      therapy despite at least one antiarrhythmic drug. The primary endpoint will be a composite of
      appropriate ICD shocks or death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appropriate ICD shocks,VT storm and death</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate ICD antitachycardia pacing anytime and after 1 month treatment period</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appropriate ICD shocks anytime and after 1 month treatment period</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate shocks anytime and after 1 month treatment period</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VT storm anytime and after 1 month treatment period</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documented sustained VT below detection rate of the ICD any time and after 1 month treatment period</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICD shocks</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for cardiac causes</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural complications, amiodarone toxicity or adverse events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Recurrent Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Ventricular Tachycardia Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalated Antiarrhythmic Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.</description>
    <arm_group_label>Ventricular Tachycardia Ablation</arm_group_label>
    <other_name>VT Ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escalated Antiarrhythmic Therapy</intervention_name>
    <description>Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.
Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.
Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day</description>
    <arm_group_label>Escalated Antiarrhythmic Drug Therapy</arm_group_label>
    <other_name>Cordarone</other_name>
    <other_name>Mexetil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior Myocardial Infarction

          -  An implantable defibrillator

          -  One of the following VT events (within the past 3 months):

               -  greater than or equal to 3 episodes of symptomatic VT treated with ATP

               -  greater than or equal to 1 appropriate ICD shock

               -  greater than or equal to 3 VT episodes within 24 hours

               -  sustained VT below detection rate of the ICD documented by ECG

          -  &quot;Failed&quot; first-line antiarrhythmic drug therapy as defined by one of:

               -  Appropriate ICD therapy or sustained VT occurred while patient was taking
                  amiodarone (stable dose &gt;/= 2 weeks)

               -  Appropriate ICD therapy or sustained VT occurred on another antiarrhythmic drug
                  (stable dose &gt;/= 2 weeks)

        Exclusion Criteria:

          -  Active ischemia (acute thrombus, dynamic ST elevation on ECG) or another reversible
             cause of VT (eg. electrolyte abnormalities, drug induced arrhythmia)

          -  Are known to be ineligible to take amiodarone (eg. active hepatitis, current
             hyperthyroidism, pulmonary fibrosis, known allergy)

          -  Are ineligible for ablation (left ventricular thrombus, implanted mechanical aortic
             and mitral valves)

          -  Renal Failure (creatinine clearance &lt; 15 ml/min)

          -  Current NYHA functional class IV heart failure or CCS Functional Class IV angina

          -  Recent ST elevation myocardial infarction (&lt; 1 month)

          -  Recent coronary bypass surgery (&lt; 3 mon) or recent PCI (&lt; 1 mon)

          -  Pregnant

          -  prior ablation for ventricular tachycardia

          -  A systemic illness likely to limit survival to &lt; 1 year

          -  Unable or unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Sapp, BSc, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ratika Parkash, MD, MSc, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony S Tang, MSc, MD, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Royal Jubilee Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George A Wells, BSc,MSc,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Univeristy of Ottawa Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William G Stevenson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1513614</url>
    <description>Publication</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>July 8, 2016</last_update_submitted>
  <last_update_submitted_qc>July 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>John Sapp</investigator_full_name>
    <investigator_title>Staff physician, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Catheter Ablation</keyword>
  <keyword>ICD therapy</keyword>
  <keyword>Antiarrhythmic Drug Therapy</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

